Reveals lower Nogo-B levels relate to vascular complications in type 2 diabetes, suggesting potential therapeutic targets.
Our study has proved that lower levels of Nogo-B are independently associated with VC in T2DM patients. In an in vitro model, Nogo-B alleviates endothelial cell injury by affecting TGF-β signalling. Further studies are still needed to support or verify our findings.
No takes yet. Share an insight, caveat, or question.
Irakoze et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: